Literature DB >> 3819209

Determinants of infarct size during permanent occlusion of a coronary artery in the closed chest dog.

T Miura, D M Yellon, D J Hearse, J M Downey.   

Abstract

One hundred nine dogs subjected to experienced experimental coronary occlusion were retrospectively examined in an attempt to identify factors influencing infarct size. A coronary artery was occluded by an embolus. The field of the occluded artery (zone at risk) was determined by subsequent autoradiography of 141-cerium-labeled microspheres that were injected into the left ventricle 2 minutes after embolization. Fifty-eight dogs were analyzed after 24 hours of embolization and 51 after 48 hours. Infarct size (assessed by tetrazolium staining) was directly proportional to the size of the zone at risk in both groups. The percent of the risk zone that developed infarction was independent of risk zone size in both the 24 and 48 hour groups. No differences were seen between male and female animals or between the dogs with left circumflex or left anterior descending artery occlusion. Infarct size was also independent of the heart rate-systolic pressure product at the time of coronary occlusion, and of the time of year. Eighty percent of the variability in the portion of the risk zone that infarcted in this population could be explained by the level of collateral flow in the risk zone 2 minutes after embolization. The linear regression between the percent of the risk zone that developed infarction and collateral flow was the same in slope and intercept between the 24 and 48 hour groups. The correlation between infarct size and collateral flow was slightly better when collateral flow was expressed as a percent of flow in the nonischemic zone than when it was expressed in absolute terms.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1987        PMID: 3819209     DOI: 10.1016/s0735-1097(87)80060-8

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

1.  Comparison of the effects of acute and chronic beta-blockade on infarct size in the dog after circumflex occlusion.

Authors:  D E Euler; P J Hughes; P J Scanlon
Journal:  Cardiovasc Drugs Ther       Date:  1988-07       Impact factor: 3.727

2.  Monitoring Canine Myocardial Infarction Formation and Recovery via Transthoracic Cardiac Strain Imaging.

Authors:  Vincent Sayseng; Rebecca A Ober; Christopher S Grubb; Rachel A Weber; Elisa Konofagou
Journal:  Ultrasound Med Biol       Date:  2020-07-27       Impact factor: 2.998

3.  Improved functional recovery after ischemic preconditioning in the globally ischemic rabbit heart is not mediated by adenosine A1 receptor activation.

Authors:  M Hendrikx; Y Toshima; K Mubagwa; W Flameng
Journal:  Basic Res Cardiol       Date:  1993 Nov-Dec       Impact factor: 17.165

4.  Limitation of myocardial necrosis with verapamil during sustained coronary occlusion in the closed-chest dog.

Authors:  J G Kingma; D M Yellon
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

5.  Calcium antagonists and acute myocardial ischemia: comparative effects of gallopamil and nifedipine on ischemia-induced and reperfusion-induced ventricular arrhythmias, epicardial conduction times, and ventricular fibrillation thresholds.

Authors:  H Gülker; W Haverkamp; G Hindricks; F Bender
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

6.  Collateral perfusion of ischemic myocardium is inversely related to the size of the ischemic zone.

Authors:  T Miura; J M Downey
Journal:  Basic Res Cardiol       Date:  1988 Mar-Apr       Impact factor: 17.165

7.  Experimental parameters and infarct size in closed chest pig LAD ischemia reperfusion models; lessons learned.

Authors:  Max J M Silvis; Gerardus P J van Hout; Aernoud T L Fiolet; Mirthe Dekker; Lena Bosch; Martijn M J van Nieuwburg; Joyce Visser; Marlijn S Jansen; Leo Timmers; Dominique P V de Kleijn
Journal:  BMC Cardiovasc Disord       Date:  2021-04-12       Impact factor: 2.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.